Partnering - Out-Licensing Strategy

Sareum is an oncology drug discovery company focused on producing targeted small molecule therapeutics to address unmet medical need in cancer.

Sareum's strategy is to partner early stage programmes with organisations that have significant cancer biology capability.

This will depend on the partner but can be in three ways:

Sponsored research whereby Sareum research costs are covered in exchange for programme ownership. The parties jointly out-license at a pre-agreed point
Research collaboration with a major partner on a jointly nominated target. The partner supports research costs of project and has first option to license the programme at a pre-agreed point
Straight license deal of a Sareum wholly owned programme at a pre-defined stage of development, e.g. Preclinical candidate nomination

Sareum’s ideal partners are oncology focused discovery and development organisations with significant expertise in cancer biology and development.

If you are interested in any of Sareum’s cancer programmes please contact us: BD@sareum.co.uk.